Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A gene therapy targeting PCSK9 achieved sustained LDL cholesterol reduction in early trials, suggesting a potentially durable approach to cardiovascular risk reduction beyond conventional statin therapy. The durability of genetic intervention raises questions about how to integrate such tools within comprehensive cardiovascular prevention strategies.
Adaptyx has demonstrated the first continuous wearable measurement of free cortisol across multiple days in humans, capturing real-time hormone dynamics rather than isolated snapshots. This shift from point-in-time testing to continuous monitoring addresses a fundamental gap in understanding how cortisol rhythms — not just absolute levels — drive metabolic health, glucose regulation, and stress resilience.
Preclinical data suggests GLP-1 therapies may accelerate late-life decline through lean mass loss and sarcopenic phenotype, particularly after treatment cessation. The research frames body composition preservation—not weight reduction alone—as central to longevity outcomes in obesity management.
A neuron-specific protein disposal mechanism called the membranal proteasome has been identified as a key player in tau aggregation and Alzheimer's pathology. This finding reframes neurodegeneration not as a mutation problem but as a failure in cellular quality control, with direct implications for how protein misfolding accumulates in the aging brain.
Environmental chemical exposures—the exposome—now explain mortality variation better than genetics, yet remain largely unmeasured in population health studies. Systematic quantification of synthetic chemicals in biobank samples could identify disease drivers and inform large-scale risk reduction.
South Korea has officially integrated ring-based cuffless blood pressure monitoring into hypertension treatment guidelines, marking the first regulatory recognition of this technology worldwide. Continuous, non-invasive monitoring addresses a critical gap in detecting masked and nocturnal hypertension—dangerous blood pressure elevations that standard clinic measurements miss.
FibroBiologics has initiated a Phase 1/2 trial of CYWC628, a fibroblast-spheroid cell therapy applied topically to diabetic foot ulcers, enrolling up to 120 patients across Australian sites. The study will assess safety, tolerability, and efficacy compared with standard care alone, with interim analysis at six weeks to evaluate wound healing and safety endpoints.
Alnylam and Inceptive have partnered to use generative AI models to accelerate RNA interference drug design, leveraging two decades of proprietary siRNA data and six approved therapeutics. This collaboration demonstrates how machine learning can compress drug development timelines by identifying optimal molecular candidates from biological datasets, with potential applications across multiple therapeutic areas.
The Revita procedure, an endoscopic duodenal remodeling intervention, preserved 78% of GLP-1-induced weight loss one year after drug discontinuation, with one-third of participants continuing to lose weight. This addresses a clinical limitation of GLP-1 therapy: rapid weight rebound upon cessation, positioning mechanical intervention as a potential bridge to sustained metabolic change.
Longeveron is advancing laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young donor bone marrow, across four clinical indications including hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company's licensing strategy at BIO 2026 signals movement toward commercialization of a cellular therapy platform with demonstrated efficacy signals across multiple disease states.
Leica Biosystems, AstraZeneca, and Daiichi Sankyo have expanded their collaboration to develop an AI-powered algorithm for detecting TROP2 biomarker expression in lung cancer tissue samples. This integration of immunohistochemistry assay development with computational pathology creates a standardized approach to identifying patients who may benefit from targeted therapies, advancing precision oncology methods.
Magnesium functions as a central regulator of mitochondrial ATP production and metabolic resilience, with age-related declines in cellular magnesium contributing to insulin resistance, metabolic inflexibility, and accelerated aging. This positions magnesium homeostasis as a mechanistic checkpoint linking energy production capacity to disease risk and longevity.